Table 1. Seropositivity of IgG antibodies against MCPyV, BKPyV and JCPyV in the general Japanese population aged 1–70 years.
| MCPyV | BKPyV | JCPyV | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ages | Total | Male | Female | Total | Male | Female | Total | Male | Female | ||||||
| % | % | (pos/No)* | % | (pos/No) | % | % | (pos/No) | % | (pos/No) | % | % | (pos/No) | % | (pos/No) | |
| 1~5 | 12 | 11 | (4/38) | 14 | (5/36) | 46 | 45 | (17/38) | 47 | (17/36) | 20 | 24 | (9/38) | 17 | (6/36) |
| 6~10 | 23 | 18 | (7/39) | 28 | (11/39) | 82 | 79 | (31/39) | 85 | (33/39) | 19 | 23 | (9/39) | 15 | (6/39) |
| 11~15 | 37 | 43 | (16/37) | 32 | (12/37) | 86 | 81 | (30/37) | 92 | (34/37) | 32 | 30 | (11/37) | 35 | (13/37) |
| 16~20 | 43 | 42 | (16/38) | 45 | (17/38) | 71 | 68 | (26/38) | 74 | (28/38) | 43 | 42 | (16/38) | 45 | (17/38) |
| 21~25 | 37 | 46 | (12/26) | 29 | (10/34) | 75 | 69 | (18/26) | 79 | (27/34) | 38 | 35 | (9/26) | 41 | (14/34) |
| 26~30 | 55 | 50 | (17/34) | 62 | (16/26) | 72 | 74 | (25/34) | 69 | (18/26) | 37 | 41 | (14/34) | 31 | (8/26) |
| 31~35 | 34 | 33 | (13/40) | 35 | (14/40) | 74 | 75 | (30/40) | 73 | (29/40) | 56 | 53 | (21/40) | 60 | (24/40) |
| 36~40 | 45 | 50 | (10/20) | 40 | (8/20) | 60 | 65 | (13/20) | 55 | (11/20) | 55 | 50 | (10/20) | 60 | (12/20) |
| 41~45 | 44 | 43 | (13/30) | 46 | (11/24) | 63 | 47 | (14/30) | 83 | (20/24) | 59 | 63 | (19/30) | 54 | (13/24) |
| 46~50 | 55 | 43 | (13/30) | 64 | (23/36) | 62 | 47 | (14/30) | 75 | (27/36) | 64 | 70 | (21/30) | 58 | (21/36) |
| 51~55 | 43 | 50 | (15/30) | 36 | (12/33) | 59 | 60 | (18/30) | 58 | (19/33) | 57 | 53 | (16/30) | 61 | (20/33) |
| 56~60 | 57 | 57 | (26/46) | 57 | (24/42) | 70 | 67 | (31/46) | 74 | (31/42) | 67 | 67 | (31/46) | 67 | (28/42) |
| 61~65 | 47 | 49 | (30/61) | 45 | (25/55) | 68 | 59 | (36/61) | 78 | (43/55) | 67 | 69 | (42/61) | 65 | (36/55) |
| 66~70 | 57 | 55 | (33/60) | 59 | (36/61) | 64 | 63 | (38/60) | 66 | (40/61) | 74 | 78 | (47/60) | 69 | (42/61) |
| Total | 43 | 43 | (225/529) | 43 | (224/521) | 68 | 64 | (341/529) | 72 | (377/521) | 51 | 52 | (275/529) | 50 | (260/521) |
* numbers of seropositive samples/numbers of samples tested